• BridgeBio published results from the Phase 3 PROPEL 3 trial of oral infigratinib in children with achondroplasia.
• Primary endpoint met: annualized height velocity increased at week 52; LS mean difference vs placebo 1.74 cm/year (95% CI 1.31-2.17); p<0.0001.
• Height z-score improved at week 52; LS mean difference vs placebo 0.32 (96% CI 0.23-0.41); p<0.0001.
• Safety profile described as well-tolerated; treatment-emergent adverse events balanced vs placebo; no treatment-related serious adverse events or discontinuations reported.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief on June 28, 2026, and is solely responsible for the information contained therein.